Molecular Partners AG

20-F13G

Schedule 13G - Passive Investments

NASDAQ
MOLN
Molecular Partners AG
SCHEDULE: UBS Asset Management Discloses 5.84% Stake in Molecular Partners AG After Filing Delay
UBS Asset Management has disclosed a 5.84% beneficial ownership stake in Molecular Partners AG, with the filing delayed due to systems integration issues following the UBS/Credit Suisse merger.
Delay expected
NASDAQ
MOLN
Molecular Partners AG
SCHEDULE 13G: Suvretta Capital and Affiliates Disclose 10.6% Stake in Molecular Partners AG
Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have jointly disclosed a significant 10.6% beneficial ownership stake in Molecular Partners AG, totaling 4,284,806 common shares.